Some providers fold everything into the medication price; others charge a separate, required membership on top. Here’s who does which, with the medication price for context.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Membership fee | Medication price (tirz) | Provenance |
|---|---|---|---|
| Fifty 410 | None | from ~$133 (tiered) | primary |
| Henry Meds | None (stated) | $179 flat | secondary |
| NexLife | None (confirmed) | $215 / ~$186 (12mo) | primary |
| Mochi Health | ~$79/mo required | ~$199 add-on (~$278 eff.) | secondary |
A membership fee isn’t inherently bad — it can bundle coaching or programming — but it must be added to the medication price to compare totals. See total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.